Central Fax: 403-955-8634 (referrals)
The NET clinic is held at the Tom Baker Cancer Centre (TBCC) on the Foothills Medical Centre campus site. The specialists regularly attending scheduled clinics are Dr. Rorstad and Dr. Parkins (Endocrinology) and Dr. Pasieka (Surgery). Ms. France Singleton is our Registered Nurse dedicated to the Clinic.
Preceding each of the two NET Clinics per month between noon and 1300 hours a meeting of the Neuroendocrine Tumor Board is convened. This multidisciplinary Tumor Board meeting includes regular representation from Endocrinology, Surgery, Medical Oncology, Nursing, Diagnostic Radiology, Interventional Radiology and Nuclear Medicine. The NET Board meeting is teleconferenced with physicians, usually medical Oncologists, in Regina, Saskatoon, and Lethbridge, depending on need. Patients for discussion are brought forth by members of the Tumor Board or the off-site Oncologists. If an expert opinion on tumor pathology is required, Dr. M. Khalil, Dept. of Pathology, kindly attends on request. Radiation oncologists support the tumor board on request.
In general order of frequency, clinic patients have a NET of the intestine, endocrine pancreas, stomach, lung or other rare sites. The most frequent syndrome of hormone hypersecretion is the Carcinoid Syndrome. Less often, syndromes of excess production of pancreatic or ectopic hormones are managed in the clinic.
Tom Baker Cancer Centre
Outpatient Fax: 403-270-8407
Parking details can be found here.
The NET Clinic provides a valuable educational experience for endocrinology (usually PGY 4 and 5) and surgery residents.
- Presently the NET Clinic participates in an international clinical trial of telotristat, a tryptophan hydroxylase inhibitor, for patients with resistant symptoms of the Carcinoid Syndrome.
- The NET clinic is involved with the Alberta Cancer Care Clinical Data Integration project which is an electronic repository of diagnostic, surveillance, treatment and outcomes information. We are interested in analysing clinical parameters that best predict a favorable outcome for patients with Neuroendocrine Tumors.